Author(s): Sasanelli M, Meignan M, Haioun C, BerrioloRiedinger A, Casasnovas RO, , Sasanelli M, Meignan M, Haioun C, BerrioloRiedinger A, Casasnovas RO,
Abstract Share this page
Abstract PURPOSE: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL). METHODS: TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent (18)F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41\% using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). RESULTS: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm(3). The 3-year estimates of PFS were 77 \% in the low metabolic burden group (TMTV ≤550 cm(3)) and 60\% in the high metabolic burden group (TMTV >550 cm(3), p = 0.04), and prediction of OS was even better (87\% vs. 60\%, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index. CONCLUSION: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
This article was published in Eur J Nucl Med Mol Imaging
and referenced in Journal of General Practice